BOSTON—11/09/2021--SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, today announced the launch and sell-out of cutting-edge GxP-compliant animal research and manufacturing facilities at 301 Binney Street and 6 Tide Street in Boston. Following the opening of its South San Francisco site in 2021, SmartLabs continues its accelerated growth with a plan to scale operations to 2 million square feet within five years. SmartLabs’ total reimagining of a contract research organization bundles tech-enabled lab infrastructure and services that allow companies to advance research from discovery to process development, animal trials, pilot-scale manufacturing and GxP execution, and clinical trials all within a single location, and without sacrificing intellectual property.
“Our new cutting-edge GxP offering further demonstrates SmartLabs’ leadership in innovative lab design and our ability to completely transform the traditional approach to biotech lab outsourcing and infrastructure. We are thrilled with the industry’s reception of our global outsourcing platform that incorporates advanced scientific infrastructure and resources for companies of varying sizes,” said Amrit Chaudhuri, CEO and co-founder of SmartLabs. “In fact, soon after opening, all GxP capacities within our 301 Binney Street location were 100 percent committed and our 6 Tide Street location is already sold out through 2024. Our further expansion into animal research and manufacturing capabilities proves we are changing the face of the drug discovery, pre-clinical and clinical development industries.”
SmartLabs currently offers flexible private lab and office spaces that are customizable to accommodate research groups from fewer than 10 to more than 200 persons on the East and West Coasts. SmartLabs delivers fully resourced environments at enterprise scale and quality that offer multifunctional research & development spaces, vivaria, process development suites, pilot-scale manufacturing, and cGMP capacity under one roof. This unique ability allows companies of all stages and sizes to launch, scale, and pivot as programs and projects rapidly evolve and advance.
“SmartLabs offers best-in-class infrastructure and services for companies that are racing to hit critical milestones. I am delighted to put a second company in a SmartLabs location at 301 Binney Street,” said Dr. Gary Glick, Chief Executive Officer and Founder of a stealth company and Founder of Scorpion Therapeutics. “SmartLabs has demonstrated that with their platform, our research can proceed faster and we can maintain control over the quality of our science, offering tremendous value not only for our company but to the patients we are serving.”
“I have been immensely impressed with the level of resourcing and flexibility of SmartLabs’ offering. The cost, time savings and control we have over our science is invaluable and provides a much-needed alternative to building, resourcing and running our own lab operations,” said Nate Dowden, Chief Operating Officer of Entrada Therapeutics.
SmartLabs’ integrated research centers have dozens of programs accelerating the development of cell therapies, gene therapies, and personalized genomic medicine. SmartLabs’ integrated and flexible resources ensure companies are better resourced and more nimble as they tackle today’s toughest scientific challenges.
SmartLabs designs, builds, and operates integrated, enterprise-grade research environments, including multifunctional research and development labs, vivaria, process development, pilot-scale manufacturing, and cGMP suites for companies of all sizes. SmartLabs currently operates four locations in Massachusetts – Kendall Square, East Cambridge, Boston Landing, and the Seaport District, as well as one location in California – South San Francisco. SmartLabs provides in-house design, architecture, and construction management, as well as full-service lab operations and facilities management and a suite of shared amenities. For more information, please email firstname.lastname@example.org or visit SmartLabs.com.